These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 35642672)

  • 1. Loss of cell division cycle‑associated 5 promotes cell apoptosis by activating DNA damage response in clear cell renal cell carcinoma.
    Huang X; Huang Y; Lv Z; Wang T; Feng H; Wang H; Du S; Wu S; Shen D; Wang C; Li H; Wang B; Ma X; Zhang X
    Int J Oncol; 2022 Jul; 61(1):. PubMed ID: 35642672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Downregulation of CDCA5 Can Inhibit Cell Proliferation, Migration, and Invasion, and Induce Apoptosis of Prostate Cancer Cells.
    Chong Y; Xue L
    Crit Rev Eukaryot Gene Expr; 2021; 31(1):29-40. PubMed ID: 33639053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DKC1 serves as a potential prognostic biomarker for human clear cell renal cell carcinoma and promotes its proliferation, migration and invasion via the NF‑κB pathway.
    Zhang M; Pan Y; Jiang R; Hou P; Shan H; Chen F; Jiang T; Bai J; Zheng J
    Oncol Rep; 2018 Aug; 40(2):968-978. PubMed ID: 29901172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CDCA5 accelerates progression of breast cancer by promoting the binding of E2F1 and FOXM1.
    Xiong Y; Shi L; Li L; Yang W; Zhang H; Zhao X; Shen N
    J Transl Med; 2024 Jul; 22(1):639. PubMed ID: 38978058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CMTM4 is frequently downregulated and functions as a tumour suppressor in clear cell renal cell carcinoma.
    Li T; Cheng Y; Wang P; Wang W; Hu F; Mo X; Lv H; Xu T; Han W
    J Exp Clin Cancer Res; 2015 Oct; 34():122. PubMed ID: 26474560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Silencing of CDCA5 inhibits cancer progression and serves as a prognostic biomarker for hepatocellular carcinoma.
    Wang J; Xia C; Pu M; Dai B; Yang X; Shang R; Yang Z; Zhang R; Tao K; Dou K
    Oncol Rep; 2018 Oct; 40(4):1875-1884. PubMed ID: 30015982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CDCA5-EEF1A1 interaction promotes progression of clear cell renal cell carcinoma by regulating mTOR signaling.
    Wang X; Shi A; Liu J; Kong W; Huang Y; Xue W; Yang F; Huang J
    Cancer Cell Int; 2024 Apr; 24(1):147. PubMed ID: 38658931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Upregulation of CDCA5 promotes gastric cancer malignant progression via influencing cyclin E1.
    Zhang Z; Shen M; Zhou G
    Biochem Biophys Res Commun; 2018 Feb; 496(2):482-489. PubMed ID: 29326043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KLF5-mediated CDCA5 expression promotes tumor development and progression of epithelial ovarian carcinoma.
    Chen X; Zhou M; Ma S; Wu H; Cai H
    Exp Cell Res; 2023 Aug; 429(1):113645. PubMed ID: 37247719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CDCA5 promotes the progression of prostate cancer by affecting the ERK signalling pathway.
    Ji J; Shen T; Li Y; Liu Y; Shang Z; Niu Y
    Oncol Rep; 2021 Mar; 45(3):921-932. PubMed ID: 33650660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CDCA5 promotes the progression of breast cancer and serves as a potential prognostic biomarker.
    Hu H; Xiang Y; Zhang XY; Deng Y; Wan FJ; Huang Y; Liao XH; Zhang TC
    Oncol Rep; 2022 Oct; 48(4):. PubMed ID: 36004470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic cancer-testis gene expression analysis identified CDCA5 as a potential therapeutic target in esophageal squamous cell carcinoma.
    Xu J; Zhu C; Yu Y; Wu W; Cao J; Li Z; Dai J; Wang C; Tang Y; Zhu Q; Wang J; Wen W; Xue L; Zhen F; Liu J; Huang C; Zhao F; Zhou Y; He Z; Pan X; Wei H; Zhu Y; He Y; Que J; Luo J; Chen L; Wang W
    EBioMedicine; 2019 Aug; 46():54-65. PubMed ID: 31324603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Knockdown of CDCA5 suppresses malignant progression of breast cancer cells by regulating PDS5A.
    Wang Y; Yao J; Zhu Y; Zhao X; Lv J; Sun F
    Mol Med Rep; 2022 Jun; 25(6):. PubMed ID: 35506437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CDCA5 promoted cell invasion and migration by activating TGF-β1 pathway in human ovarian cancer cells.
    Zhang Q; Zhang R; Li Y; Yang X
    J Ovarian Res; 2024 Mar; 17(1):68. PubMed ID: 38539247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SPOP promotes CDCA5 degradation to regulate prostate cancer progression via the AKT pathway.
    Luo Z; Wang J; Zhu Y; Sun X; He C; Cai M; Ma J; Wang Y; Han S
    Neoplasia; 2021 Oct; 23(10):1037-1047. PubMed ID: 34509929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. circCHST15 is a novel prognostic biomarker that promotes clear cell renal cell carcinoma cell proliferation and metastasis through the miR-125a-5p/EIF4EBP1 axis.
    Gui CP; Liao B; Luo CG; Chen YH; Tan L; Tang YM; Li JY; Hou Y; Song HD; Lin HS; Xu QH; Yao GS; Yao HH; Xi-Liu ; Luo JH; Cao JZ; Wei JH
    Mol Cancer; 2021 Dec; 20(1):169. PubMed ID: 34922539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic potential of targeting cell division cycle associated 5 for oral squamous cell carcinoma.
    Tokuzen N; Nakashiro K; Tanaka H; Iwamoto K; Hamakawa H
    Oncotarget; 2016 Jan; 7(3):2343-53. PubMed ID: 26497678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Higher expression of cell division cycle-associated protein 5 predicts poorer survival outcomes in hepatocellular carcinoma.
    Hou S; Chen X; Li M; Huang X; Liao H; Tian B
    Aging (Albany NY); 2020 Jul; 12(14):14542-14555. PubMed ID: 32694239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. YAP is overexpressed in clear cell renal cell carcinoma and its knockdown reduces cell proliferation and induces cell cycle arrest and apoptosis.
    Cao JJ; Zhao XM; Wang DL; Chen KH; Sheng X; Li WB; Li MC; Liu WJ; He J
    Oncol Rep; 2014 Oct; 32(4):1594-600. PubMed ID: 25175178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CDCA5 overexpression is an Indicator of poor prognosis in patients with hepatocellular carcinoma (HCC).
    Tian Y; Wu J; Chagas C; Du Y; Lyu H; He Y; Qi S; Peng Y; Hu J
    BMC Cancer; 2018 Nov; 18(1):1187. PubMed ID: 30497429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.